# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Sean Dodge maintains Avid Bioservices (NASDAQ:CDMO) with a Outperform and raises the price target from $...
Avid Bioservices (NASDAQ:CDMO) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(...
Stephens & Co. analyst Jacob Johnson maintains Avid Bioservices (NASDAQ:CDMO) with a Overweight and lowers the price tar...